Aim Immunotech Inc (AIM)

$0.21 +0.02 (8.42%)
Market Cap 12.58M
Revenue (ttm) 200,000.00
Net Income (ttm) -28.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14,480.00%
Debt to Equity Ratio 0.05
Volume 925,500
Avg Vol 624,192
Day's Range N/A - N/A
Shares Out 63.78M
Stochastic %K 43%
Beta -0.36
Analysts Strong Sell
Price Target $2.75

Latest News on AIM

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Jan 15, 2025, 9:05 AM EST - 2 days ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 4:45 PM EST - 4 weeks ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 17, 2024, 3:10 PM EST - 4 weeks ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 16, 2024, 8:00 AM EST - 4 weeks ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 14, 2024, 4:54 PM EST - 4 weeks ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Dec 12, 2024, 3:00 PM EST - 5 weeks ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Dec 12, 2024, 9:00 AM EST - 5 weeks ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Kellner Group Announces Support from Another Former AIM Senior Executive

Dec 12, 2024, 8:16 AM EST - 5 weeks ago

Kellner Group Announces Support from Another Former AIM Senior Executive

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 11, 2024, 7:30 AM EST - 5 weeks ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Dec 10, 2024, 10:20 AM EST - 5 weeks ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Dec 10, 2024, 7:30 AM EST - 5 weeks ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Dec 6, 2024, 9:15 AM EST - 6 weeks ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

Dec 6, 2024, 8:34 AM EST - 6 weeks ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

Dec 5, 2024, 9:00 AM EST - 6 weeks ago

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

Dec 2, 2024, 8:00 AM EST - 6 weeks ago

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

Nov 27, 2024, 3:30 PM EST - 7 weeks ago

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

AIM ImmunoTech Announces Cash Conservation Plan

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

AIM ImmunoTech Announces Cash Conservation Plan

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

Nov 25, 2024, 8:00 AM EST - 7 weeks ago

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

Nov 19, 2024, 8:00 AM EST - 2 months ago

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 10:32 AM EST - 2 months ago

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 15, 2024, 7:29 AM EST - 2 months ago

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:04 PM EST - 2 months ago

Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

Nov 6, 2024, 9:00 AM EST - 2 months ago

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Nov 4, 2024, 8:00 AM EST - 2 months ago

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

Oct 3, 2024, 8:45 AM EDT - 3 months ago

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Sep 27, 2024, 8:00 AM EDT - 4 months ago

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Aug 20, 2024, 8:30 AM EDT - 5 months ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 11:13 AM EDT - 5 months ago

AIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call Transcript

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 16, 2024, 7:00 AM EDT - 5 months ago

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aimia Inc. (AIMFF) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 1:42 PM EDT - 5 months ago

Aimia Inc. (AIMFF) Q2 2024 Earnings Call Transcript

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

Aug 13, 2024, 9:05 AM EDT - 5 months ago

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Jul 29, 2024, 9:15 AM EDT - 6 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy

Jul 24, 2024, 8:50 AM EDT - 6 months ago

AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Jun 10, 2024, 8:55 AM EDT - 7 months ago

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

Jun 3, 2024, 9:15 AM EDT - 8 months ago

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

May 31, 2024, 8:30 AM EDT - 8 months ago

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

May 20, 2024, 9:15 AM EDT - 8 months ago

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript

May 16, 2024, 11:24 AM EDT - 8 months ago

AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 16, 2024, 7:30 AM EDT - 8 months ago

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Aimia Inc. (AIMFF) Q1 2024 Earnings Call Transcript

May 15, 2024, 12:05 PM EDT - 8 months ago

Aimia Inc. (AIMFF) Q1 2024 Earnings Call Transcript

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

May 9, 2024, 8:50 AM EDT - 9 months ago

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

May 6, 2024, 8:30 AM EDT - 9 months ago

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Apr 29, 2024, 8:55 AM EDT - 9 months ago

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

Apr 15, 2024, 8:55 AM EDT - 9 months ago

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Apr 10, 2024, 8:21 AM EDT - 10 months ago

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 11:32 AM EDT - 10 months ago

AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Apr 2, 2024, 7:30 AM EDT - 10 months ago

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

Mar 28, 2024, 8:05 AM EDT - 10 months ago

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

Aimia Inc. (AIMFF) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 11:55 AM EDT - 10 months ago

Aimia Inc. (AIMFF) Q4 2023 Earnings Call Transcript

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

Mar 26, 2024, 9:05 AM EDT - 10 months ago

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast